m6skq – HTA office

Full Text Articles

Mon, 17 Mar 2025 01:17:59 +0000

Pöllinger B, Haiderali A, Huang M, Akyol Ersoy B, Abdelaziz AH, Kassem L, Elsisi GH. The cost-effectiveness of treatment for high-risk, early-stage, triple-negative breast cancer in Egypt: an analysis of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab. J Med Econ. 2025 Dec;28(1):105-113. doi: 10.1080/13696998.2024.2441073. Epub 2025 Jan 3. PMID: 39665251.

Elsisi, G. H., Waleed, A. A., Shehhy, W. A., & Farghaly, M. (2024). Microsimulation model of the cost-effectiveness of anifrolumab compared to belimumab in the United Arab Emirates. Journal of medical economics, 27(sup1), 23–34.

Elsisi, G. H., Quintana, G., Gil, D., Santos, P., & Fernandez, D. (2024). Clinical and economic burden of systemic lupus erythematosus in Colombia. Journal of medical economics, 27(sup1), 1–11.
Elsisi, G. H., Hsieh, S. C., & Chen, D. Y. (2024). The economic burden of systemic lupus erythematosus in Taiwan. Journal of medical economics, 27(sup1), 56–66.

Alansari, A., Hannawi, S., Aldhaheri, A., Zamani, N., Elsisi, G. H., Aldalal, S., Naeem, W. A., & Farghaly, M. (2024). The economic burden of systemic lupus erythematosus in United Arab Emirates. Journal of medical economics, 27(sup1), 35–45.

Elsisi, G. H., Joe, A. Y., Zain, M. M., Yusoof, H. M., Teh, C. L., Mohd, A. B., Khor, X. T., & Isa, L. B. M. (2024). Economic burden of systemic lupus erythematosus in Malaysia. Journal of medical economics, 27(sup1), 46–55.

Elsisi, G. H., Andrade-Ortega, L., Portela, M., & Ramírez, G. M. (2024). The economic burden of systemic lupus erythematosus in Mexico. Journal of medical economics, 27(sup1), 12–22.

Elsisi G, Ezzat M, Ramadan M. Projecting the Potential Budget Impact Analysis of Paliperidone Palmitate in Egyptian Adult Patients with Schizophrenia. JHEOR. 2023;10(2):23-29. doi:10.36469/001c.83240

Gihan Hamdy Elsisi, Mariam Mohamed El-Attar, Shaimaa Mohamed Ismaeil, et al; Estimation of Prostate Cancer Cost in Egypt From a Societal Perspective. Global Journal on Quality and Safety in Healthcare 1 May 2023; 6 (2): 33–41. doi: https://doi.org/10.36401/JQSH-22-20

Ahmed Swidan, Gihan Hamdy Elsisi, Mohamed M. Ibrahim, Mohammad Aljazzar & Hossameldin Tawfik Sallam (2023) Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait, Journal of Medical Economics, 26:1, 271-282, DOI: 10.1080/13696998.2023.2174749

Elsisi GH, Afify A, Abgad A, Zakaria I, Nasif N, Ibrahim HN, Raafat N, Carapinha JL.(2022) A budget impact analysis of substituting sitagliptin with liraglutide in type 2 diabetes from a private health insurance perspective in Egypt. Cost Eff Resour Alloc. 2022 Jan 15;20(1):1. doi: 10.1186/s12962-021-00335-y. PMID: 35033094; PMCID: PMC8760653.

Abdelhamid M, Elsisi GH, Seyam A, Shafie A, Kirollos M, Emad S, Mansy S, Sobhy M. (2022) Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt. J Med Econ. 2022 Jan-Dec;25(1):450-456. doi: 10.1080/13696998.2022.2054226. PMID: 35291896.

Elsamany S, Elsisi GH, Mohamed Hassanin FA, Saleh K, Tashkandi E. (2021) Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia. Value Health Reg Issues. 2022 Mar;28:67-75. doi: 10.1016/j.vhri.2021.07.001. Epub 2021 Nov 18. PMID: 34801961.

Shereef Elsamany, Gihan Hamdy Elsisi, Fayza Hassanin & Mohamed Jafal (2020) Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2- positive breast cancer patients., Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2021.1860024.

Gihan Hamdy Elsisi, João L. Carapinha , Rania Afify , Mohamed Abd Elmoty & Mohamed Khalaf (2020). A budget impact analysis of lenalidomide in multiple myeloma Egyptian patients, Journal of Medical Economics. DOI: 10.1080/13696998.2020.1796288

Gihan Hamdy Elsisi, Mohammed Moustapha Anwar, Mohamed Khattab, Ibrahim Elebrashy, Alaa Wafa, Hemat Elhadad, Mohamad Awad & João L. Carapinha (2020). Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt, Journal of Medical Economics. DOI: 10.1080/13696998.2020.1764571

Gihan Hamdy Elsisi, Yousery Nada, Noha Rashad, João Carapinha, Ahmad O. Noor, Diena M. Almasri, Mostafa Al Zaidy, Ahmed Foad & Hussien Khaled (2019). Cost effectiveness of six months versus 1 year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt, Journal of Medical Economics. https://doi.org/10.1080/13696998.2020.1724682

Aya Mostafa, Manal H. El-Sayed, Mohamed El Kassas, Manal Elhamamsy, Gihan Hamdy Elsisi. Safety-Engineered Syringes: An Intervention to Decrease Hepatitis C Burden in Developing Countries: A Cost-Effectiveness Analysis from Egypt. VALUE IN HEALTH REGIONAL ISSUES 19 (2019) 51 – 8.

Gihan Hamdy Elsisi, João Carapinha ,Wagdy Amin, Ehab Thabet, Safaa Elafify, Mohamad Amin & Ashraf Hatem (2019) A budget impact analysis of budesonide /formoterol in patients with mild asthma in Egypt, Journal of Medical Economics. https://doi.org/10.1080/13696998.2019.1642899

Gihan Hamdy Elsisi, Yousery Nada, Noha Rashad & João Carapinha (2018) Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt, Journal of Medical Economics, DOI: 10.1080/13696998.2018.1552432

Aya Mostafa & Gihan Hamdy Elsisi. A cost-effectiveness analysis of the use of safety-engineered syringes in reducing HBV, HCV, and HIV burden in Egypt, Expert Review of Medical Devices (2018), DOI: 10.1080/17434440.2019.1561267

Elsayed TM, Elsisi GH, Elmahdawy M, Pharmacy Practice in Egypt. In: Fathelrahman A, Izham M. Pharmacy Practice in Developing Countries: Achievement and Challenges. Academic press, 2016. It can be accessed via Elsevier at: http://store.elsevier.com/product.jsp?isbn=9780128017142

Gericke CA, Britain K, Elmahdawy M, Elsisi G. The Health System in Egypt. In: E. V. Ginneken, R. Busse (eds.), Health Care Systems and Policies, Health Services Research, New York: Springer, 2018.

Elmahdawy M, Elsisi GH, Carapinha J et al. Ebola Virus Epidemic in West Africa: Global Health Economic Challenges, Lessons Learned, and Policy Recommendations. Value In Health Regional Issues 13C(2017)67 – 70.

Elsisi GH, Aburawash A, Waked E. Cost-Effectiveness Analysis of New Hepatitis C Virus Treatments in Egyptian Cirrhotic and Noncirrhotic Patients: A Societal Perspective. Value In Health Regional Issues 13C(2017)7 – 15.

Elhamamsy MH, Elsisi GH, Eldessouki R, Elmazar MM, Taha AS, Awad BF, Elmansy H. Economic Evaluation of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Mechanical Valve Prostheses. Applied Health Economics and Health Policy Journal 2016; 14: 431.

Kalo Z, Alabbadi I, Al Ahdab O, Alowayesh M, Elmahdawy M, Al-Saggabi A, Tanzi V, Al-Badriyeh D, Alsultan H, Ali F, Elsisi G, Akhras K, Voko Z and Kanavos P. Implications of external price referencing of pharmaceuticals in Middle 5 East countries. Expert Rev. Pharmacoecon. Outcomes Res. 2015; 15(6).

Elsisi GH, Eldessouki R, Kaló Z, Elmazar MM, Taha AS, Awad BF, Elhamamsy MH. Cost-Effectiveness of the Combined Use of Warfarin and Low- Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov Model. Value in Health RI 2014: 4C 24-30.

Elsisi GH, Kaló Z, Eldessouki R, Elmahdawy MD, Saad A, Ragab S, Elshalakani A, Abaza. Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt. Value in Health RI 2013:2;319-327.

Elsisi G H, Raising Awareness and Improving the Decision-Making Process in Government to Make Better Use of Health Care Resources, ISPOR Connections November/ December 2011,Vol.17. No.6, p.19.

]]>

Published Posters

Mon, 17 Mar 2025 01:15:21 +0000

EE407 Budget Impact Analysis of Paliperidone Palmitate in Chronic Schizophrenia in the Mental Health Secretariat-Egyptian Ministry of Health. Elsisi, G et al. Value in Health, Volume 27, Issue 12, S135 November 17-20 2024, Barcelona, Spain

EE186 Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Qatar Hamad, A et al. Value in Health, Volume 27, Issue 12, S90
November 17-20 2024, Barcelona, Spain

EE515 Cost-Effectiveness Analysis of Sacubitril/Valsartan in Heart Failure Patients in Egypt
Khalil, A et al. Value in Health, Volume 27, Issue 12, S157
November 17-20 2024, Barcelona, Spain

EE624 Budget Impact of Intravenous Eptinezumab in the Prevention of Chronic Migraine Patients in United Arab Emirates Elattar, M et al. Value in Health, Volume 27, Issue 12, S178
November 17-20 2024, Barcelona, Spain

RWD131 Budget Impact Analysis of Emicizumab in Hemophilia A Pediatric Patients From Payer Perspective in Egypt Awadallah, M. et al. Value in Health, Volume 27, Issue 12, S598 – S599
November 17-20 2024, Barcelona, Spain

Gihan Hamdy Elsisi, Mary Gergis, Amal Samir, Ahmed Elagamy, Ahmed Seyam, Mariam Eldebeiky, Randa
Eldessuoki. HTA341, Egyptian Guidelines for Pharmacoeconomic Evaluations: toward
Standardization of Drug Reimbursement Applications. November 12-15 2023, Copenhagen, Denmark
https://www.ispor.org/docs/default-source/euro2023/guidelines-poster128687-pdf.pdf?sfvrsn=975e1b81_0

G. Elsisi, M. Elattar, N. Eldesouky, EE260 Cost-Effectiveness Analysis of Daratumumab Triplet Therapy Vs Carfilzomib Duplet Therapy in Patients with Relapsed or Refractory Multiple Myeloma in Egypt from Payer Perspective, Value in Health, Volume 26, Issue 12, Supplement, 2023,Page S101,ISSN 1098- 3015, https://doi.org/10.1016/j.jval.2023.09.527

M. Elattar, A.H. Abdelaziz, B. Eshaak, E. Shash, H. El-Zawahery, H. Tawfik, I. Saad, K.A.A. Kamal, M. Elgazzar, M.S. Alkady, S. Shehata, T. Hashem, Y. Nada, G. Elsisi, CO92 Clinician-Reported Outcome Measure for Palonosetron Versus Standard of Care in Chemotherapy-Induced Nausea and Vomiting in Egypt, Value in Health, Volume 26, Issue 12, Supplement, 2023, Page S31, ISSN 1098-3015, https://doi.org/10.1016/j.jval.2023.09.164

Economic evaluation of generic Tacrolimus and the innovator in renal transplant recipients in Egypt, EE288: Poster presentation, 8 November 2022, Vienna, Austria. https://www.valueinhealthjournal.com/article/S1098-3015(22)02739-5/fulltext

Hamouda M, Awad H, Elsisi G. (2022) Budget Impact Analysis of an Alternative Meningococcal Conjugate Vaccine for High-Risk Infants in Egypt. Value in Health. Poster presentation: POSC121

Moussa M….Elsisi G. A Cost effectiveness study of percutaneous coronary intervention versus CABG in Egypt for patient with previously untreated three vessel or left main CAD: Markov Model (2021) A Cost effectiveness study of percutaneous coronary intervention versus CABG in Egypt for patient with previously untreated three vessel or left main CAD: Markov Model. Value in Health · Poster presentation: PCV13

Elkony M, Elsisi G. Cost Minimization Analysis of Secukinumab versus Infliximab in Egyptian Patients with Ankylosing Spondylitis from Health Care Provider Perspective. Poster presentation PMS59 at ISPOR 21th Annual European Congress, November 2018; Barcelona, Spain.

Assal R, Elsisi G. Cost Effectiveness Analysis of Pegylated Liposomal and Nonliposomal Doxorubicin Formulations for the First Line Treatment of Metastatic Breast Cancer from Patient Perspective in Egypt. Poster presentation PCN160 at ISPOR 21th Annual European Congress, November 2018; Barcelona, Spain.

Elsisi G, Emad S, Hamed A. Are There Enough Regulations to Combat the Poor Quality Povidone-Iodine in Egypt. Poster presentation PHP341 at ISPOR 21th Annual European Congress, November 2018; Barcelona, Spain.

Abu Rawash A, Elsisi G. Cost-Effectiveness Analysis of Everolimus Plus Exemestane versus Exemestane Alone For Treatment of Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer from Private Sector Prespective in Egypt. Poster presentation PCN154 at ISPOR 21th Annual European Congress, November 2018; Barcelona, Spain.

Fouad S, Elsisi G. Cost-Utility of Switching to Fingolimod in Treating Patients with Relapsing-Remitting Multiple Sclerosis: A Health Insurance Perspective. Poster presentation PND75 at ISPOR 21th Annual European Congress, November 2018; Barcelona, Spain.

Elwahsh N, Elsisi G. Cost Effectiveness of Voriconazole versus Conventional Amphotericin B for Invasive Aspergillosis in Immunocompromised Egyptian Patients Decision-Analytical Model. Poster presentation PIN58 at ISPOR 21th Annual European Congress, November 2018; Barcelona, Spain.

Elshafie Z, Elsisi G, Botros A. Cost-Minimization Analyses Of Biological Therapies In The Treatment Of Rheumatoid Arthritis From The Egyptian Healthcare System Perspective. Poster presentation PMS53 at ISPOR 20th Annual European Congress, November 2017; Scottish Event Campus in Glasgow, Scotland.

Elshafie Z, Elsisi G. Economic Evaluation Of Exemestane Versus Tamoxifen In Post-Menopausal Women With Early Breast Cancer From The Egyptian Health Care System Perspective poster presentation PCN157 at ISPOR 20th Annual European Congress, November 2017; Scottish Event Campus in Glasgow, Scotland.

Elkony M. Elsisi G. Cost Effectiveness Analysis Of Sorafenib Versus Best Supportive Care In Patients With Advanced Hepatocellular Carcinoma From Health Care System Perspective In Egypt. Poster presentation PCN152 at ISPOR 20th Annual European Congress, November 2017; Scottish Event Campus in Glasgow, Scotland.

Griffin A, Elsisi G, Ragab S, Ziada R, Abushadi R, Safori S, Khatabi N, Atef M, Ashraf, R. Setting Recommendations For Good Practice Of Health Technology Assessment In The Egyptian Ministry Of Health. Poster Presentation PHP326 at ISPOR 19th Annual European Congress October 2016; Austria Center Vienna, Vienna, Austria.

Abdullah H, ElSisi GH. Cost-Effectiveness Analysis Of Fidaxomicin Versus Oral Vancomycin For The Treatment Of Clostridium Difficile Infection In Egypt Poster Presentation PGI22 at ISPOR 19th Annual European Congress October 2016; Austria Center Vienna, Vienna, Austria.

Abu Rawash A, Eldessouki R, ElSisi GH. Cost Effectiveness Analysis Of Nilotinib Versus Imatinib In Newly Diagnosed Chronic Myeloid Leukemia From The Health Insurance Perspective In Egypt. Poster Presentation PCN151 at ISPOR 19th Annual European Congress October 2016; Austria Center Vienna, Vienna, Austria.

Fahim M, Asl R, Mamdouh M, ElSisi GH. Cost Minimization Analysis of Bevacizumab Versus Cetuximab And Panitumumab In The Management of Colorectal Cancer From Patient Perspective In Egypt. Poster Presentation PCN166 at ISPOR 19th Annual European Congress October 2016; Austria Center Vienna, Vienna, Austria.

Fouad S, ElSisi GH. Cost Effectiveness of Darbepoetin Alfa Versus Epoetin Alfa in The Management of Anemic Patients with Chronic Kidney disease: the Health insurance Perspective. Poster Presentation PSY79 at ISPOR 19th Annual European Congress October 2016; Austria Center Vienna, Vienna, Austria.

Mohamed M, ElSisi GH, Elmazar MM, Taha AS, Awad BF, Elhamamsy MH. Cost Effectivess Analysis For Combination Of Aspirin And Warfarin Versus Warfarin Alone In Patients With Heart Valve Prosthesis. Poster Presentation PCV30 at ISPOR 7th Asia-Pacific Conference September 2016; Suntec Singapore Convention & Exhibition Center, Singapore.

Ragab S, ElSisi GH, Abo Shady R, Hassan R, Abaza S, Abbas Y, Shaheen M, Kalo Z. Challenges That Face The Applicability Of Multi-Indication Pricing For Innovative Products In Egypt. Poster Presentation PHP205 at ISPOR 21st Annual International Meeting, Washington, DC, USA.

Ragab S, ElSisi GH, Abo Shady R, Hassan R, Abaza S, Abbas Y, Shaheen M, Kalo Z, Diaa M. Pricing Policy For Pharmaceuticals In Egypt: Challenges And Opportunities. Poster Presentation PHP51 at ISPOR 18th Annual European congress, Milan, Italy.

Elmansy H, Metry A, Eldessouki R, ElSisi GH. Cost-Effectiveness of Zoledronic Acid Versus Alendronic Acid In The Treatment of Osteoporosis In Postmenopausal Egyptian Patients: Decision Analysis. Poster Presentation PMS71 at ISPOR 18th Annual European congress, Milan, Italy.

ElSisi GH, Abdullah H, Elmansy H. Economic Evaluation Of Lidocaine/ Tetracaine Patch Versus Lidocaine/ Prilocaine Cream For Topical Anaesthesia Before Vascular Access In Egypt. Poster Presentation PSY59 at ISPOR 18th Annual European congress, Milan, Italy.

ElSisi GH, Said E, Elmahdawy MD. Budget Impact Analysis of Everolimus Plus Exemestane Versus Gemcitabine Plus Paclitaxel And Capecitabine Plus Docetaxel In Metastatic Breast Cancer Patients In Egypt. Poster Presentation PCN49 at ISPOR 17th Annual European congress, Amsterdam, The Netherlands.

Helal M, ElSisi GH. Cost-Effectiveness of Aprepitant In Egyptian Patients Receiving Highly Emetogenic Therapy From The Third Party Payer Perspective. Poster Presentation PCN114 at ISPOR 17th Annual European congress, Amsterdam, The Netherlands.

ElSisi GH, Said E, Abo Taleb AM. Economic Evaluation of Lapatinib in HER-2-Positive Metastatic Breast Cancer Patients in Egypt. Poster Presentation PCN159 at ISPOR 17th Annual European congress, Amsterdam, The Netherlands.

Metry AB, ElSisi GH, Abou Rawash AS, Abo Taleb A. Cost Minimization Analysis Of U100 Insulin And U40 Insulin In Egyptian Diabetic Patients. Poster Presentation PDB28 at ISPOR 6th Asia-Pacific Conference September 2014; Beijing, China.

Metry AB, ElSisi GH, Abou Rawash AS, Eldessouki R. Budget Impact Analysis Of U100 Insulin In Egyptian Diabetic Patients. Poster Presentation PDB14 at ISPOR 6th Asia-Pacific Conference September 2014; Beijing, China.

Elsisi GH, Hassouna A, Abo Taleb AM, Elmahdawy MD. Cost-effectiveness Of Pazopanib Versus Sunitinib In Egyptian Patients With Metastatic Renal Cell Carcinoma From The Health Insurance Perspective: A Markov Model. Poster Presentation PCN131 at ISPOR 19th Annual International Meeting 31 May – 4 June 2014; Montreal, Canada.

Elsisi GH, Ragab S, Ashraf R, Elmahdawy M. Cost-Effectiveness of Drug-Eluting Stents versus Bare Metal Stents in Egyptian Diabetic Patients. Poster Presentation PCV108 at ISPOR 16th Annual European Congress 2-6 November 2013; Dublin, Ireland.

Elsisi GH, Elmahdawy MD, Abaza S, Elshalakani A. Cost-Effectiveness Of Sapropterin Versus Phenylalanine Free Diet In Patients With Phenylketonuria In Egypt. Poster Presentation PSY45 at ISPOR 16th Annual European Congress 2-6 November 2013; Dublin, Ireland.

ElSisi G, Botros A & Sharaf Eldeen M. Limitations Of Egyptian Current Pricing System, Poster Presentation Pcase2 at ISPOR 15th Annual European Congress 3-7 November 2012; Berlin, Germany.

Soliman AM, ElSisi G, Diaa M & Abdulhalim AM. The Status of Pharmacoeconomic Education In Egyptian Schools Of Pharmacy: An Exploratory Analysis.Value In Health 2012, Vol. 15, No.4. Poster Presentation PHP72 at ISPOR 17th Annual International Meeting Washington, DC, USA.

Elsisi GH, Hassouna A, Abo Taleb AM, Elmahdawy MD. Cost-effectiveness Of Pazopanib Versus Sunitinib In Egyptian Patients With Metastatic Renal Cell Carcinoma From The Health Insurance Perspective: A Markov Model. Poster Presentation PCN131 at ISPOR 19th Annual International Meeting 31 May – 4 June 2014; Montreal, Canada.

Elsisi GH, Ragab S, Ashraf R, Elmahdawy M. Cost-Effectiveness of Drug-Eluting Stents versus Bare Metal Stents in Egyptian Diabetic Patients. Poster Presentation PCV108 at ISPOR 16th Annual European Congress 2-6 November 2013; Dublin, Ireland.

Elsisi GH, Elmahdawy MD, Abaza S, Elshalakani A. Cost-Effectiveness Of Sapropterin Versus Phenylalanine Free Diet In Patients With Phenylketonuria In Egypt. Poster Presentation PSY45 at ISPOR 16th Annual European Congress 2-6 November 2013; Dublin, Ireland.

ElSisi G, Botros A & Sharaf Eldeen M. Limitations of Egyptian Current Pricing System. Poster Presentation Pcase2 at ISPOR 15th Annual European Congress 3-7 November 2012; Berlin, Germany.

Soliman AM, ElSisi G, Diaa M & Abdulhalim AM. The Status of Pharmacoeconomic Education In Egyptian Schools Of Pharmacy: An Exploratory Analysis.Value In Health 2012, Vol. 15, No.4. Poster Presentation PHP72 at ISPOR 17th Annual International Meeting Washington, DC, USA.

Elkony M, Elsisi G. Cost Minimization Analysis of Secukinumab versus Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, and Infliximab In Egyptian Patients with Ankylosing Spondylitis From Private Sector Perspective. Poster presentation PMS61 at ISPOR 21th Annual European Congress, November 2018; Barcelona, Spain.

]]>